DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: : “Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
Generally, economists suggest that one additional year in perfect health in the U.S. is worth somewhere between $50,000 and $200,000 a year. 
Allergan, which is selling its generics business to focus on branded drugs and aesthetics products, aims to acquire or license products that have already shown promise in studies, and leave the riskier discovery process to small biotechs and academic researchers.
Eli Lilly and Company (LLY) today notified the University of California, San Diego (UCSD) of its intent to end its contract with the university for the management of the Anti-amyloid Treatment in Asymptomatic Alzheimer's disease (A4) study. The A4 study is a novel clinical trial testing solanezumab in the preclinical stage of Alzheimer's disease in older individuals who have evidence of amyloid in their brains on a PET scan, but do not show symptoms of memory impairment. 
A limited use approval pathway is one of the more intriguing components of the “21st Century Cures” FDA reform provisions. As the legislation moves to the Senate, FDA is joining other stakeholders to outline its vision for how the new authority would work. https://www.pharmamedtechbi.com/publications/rpm-report/first-take/2015/3/lpad
